OCULAR THERAPEUTIX, INC — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Ocular Therapeutix reported Q3 2026 results with cash of $530.6M (sufficient runway into 2028) and announced AXPAXLI NDA submission on track for Q4 2026 under 505(b)(2) pathway for wet AMD, supported by SOL-1 Week 52 efficacy data and interim SOL-R Week 52 safety data from >300 patients. SOL-R primary endpoint moved to Week 40 (from Week 56) to preserve statistical integrity ahead of interim safety analysis; preliminary SOL-R screening shows ~20% of otherwise eligible subjects excluded due to early persistent retinal fluid, aligned with company expectations. Company appointed commercial veteran Riad Sherif to Board; Q3 net loss was $94.8M on revenue of $12.9M.
Why this rating
NDA submission is major near-term regulatory milestone for lead asset representing potential market transformation for company. Relative to $1.6B market cap, successful approval could unlock substantial revenue; however, outcome remains uncertain pending FDA review. Positive pre-NDA meeting alignment and 505(b)(2) pathway advantage provide credibility, but clinical risk persists.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $6.12 ▼ 1.21% | at our read · unknown $6.20 | +10 min · unknown $6.19 ▼ 0.08% | +30 min · unknown $6.41 ▲ 3.39% | +1 hr · unknown $6.43 ▲ 3.79% | +4 hrs · unknown $6.66 ▲ 7.51% |
The stock had already moved +1.23% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.